Join

Compare · BVXV vs GILD

BVXV vs GILD

Side-by-side comparison of BiondVax Pharmaceuticals Ltd. (BVXV) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BVXV and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • GILD is the larger of the two at $155.82B, about 5056.7x BVXV ($30.8M).
  • GILD has hit the wire 20 times in the past 4 weeks while BVXV has been quiet.
  • GILD has more recent analyst coverage (25 ratings vs 1 for BVXV).
MetricBVXVGILD
Company
BiondVax Pharmaceuticals Ltd.
Gilead Sciences Inc.
Price
$1.32-2.22%
$125.46-2.11%
Market cap
$30.8M
$155.82B
1M return
-
-4.46%
1Y return
-
+13.97%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2015
1992
News (4w)
0
20
Recent ratings
1
25
BVXV

BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and related illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

GILD

Gilead Sciences Inc.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Latest BVXV

Latest GILD